Comparative Pharmacology
Head-to-head clinical analysis: THYROLAR 3 versus UNITHROID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THYROLAR 3 versus UNITHROID.
THYROLAR-3 vs UNITHROID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
THYROLAR-3 is a combination of synthetic T4 (levothyroxine) and T3 (liothyronine) that replaces or supplements endogenous thyroid hormones. T4 is converted to the active T3 in peripheral tissues. Thyroid hormones bind to thyroid hormone receptors (TRα and TRβ), regulating gene transcription involved in metabolism, growth, and development.
Synthetic T4 (levothyroxine) is converted to T3, which binds to thyroid hormone receptors to regulate gene transcription, increasing basal metabolic rate.
Adults: Initial dose 30 mg orally once daily; adjust based on thyroid function tests. Typical maintenance dose 60-120 mg once daily.
Initial adult dose: 25-50 mcg orally once daily; titrate by 12.5-25 mcg every 4-6 weeks based on TSH; typical maintenance: 75-150 mcg orally once daily; maximum dose up to 300 mcg daily in severe hypothyroidism.
None Documented
None Documented
Levothyroxine (T4): 6-7 days; Liothyronine (T3): 1-2 days. Clinical context: In hyperthyroidism, half-life shortened; in hypothyroidism, prolonged.
6-7 days for L-thyroxine (T4) in euthyroid patients; prolonged to 9-10 days in hypothyroidism, shortened to 3-4 days in hyperthyroidism. Clinical context: once-daily dosing achieves steady state in 6-8 weeks.
Renal (approximately 50% as unchanged drug and conjugates); fecal (~20%); biliary (~10%)
Renal (approx. 20-40% as unchanged drug and glucuronide conjugates); fecal (minor, via bile).
Category C
Category C
Thyroid Hormone
Thyroid Hormone